Detalhe da pesquisa
1.
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.
Blood;
2024 Mar 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38484137
2.
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Haematologica;
108(1): 98-109, 2023 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35833303
3.
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Am J Hematol;
98(11): 1751-1761, 2023 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37668287
4.
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Lancet Oncol;
23(8): 1055-1065, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35803286
5.
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
Br J Haematol;
199(1): 76-85, 2022 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35861370
6.
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw;
20(4): 387-405, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35390769
7.
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.
Ann Hematol;
100(10): 2529-2539, 2021 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34304287
8.
Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies.
Future Oncol;
17(27): 3549-3560, 2021 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34154392
9.
Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program.
Biol Blood Marrow Transplant;
26(8): 1386-1393, 2020 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32439475
10.
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
J Natl Compr Canc Netw;
18(3): 230-241, 2020 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32135517
11.
Management of Immunotherapy-Related Toxicities, Version 1.2019.
J Natl Compr Canc Netw;
17(3): 255-289, 2019 03 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30865922
12.
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.
Biol Blood Marrow Transplant;
24(3): 514-520, 2018 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29196080
13.
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
Br J Haematol;
183(4): 601-607, 2018 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30596402
14.
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Blood;
127(24): 2980-90, 2016 06 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27118452
15.
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Mol Ther;
25(1): 285-295, 2017 Jan 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28129122
16.
Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.
Biol Blood Marrow Transplant;
23(11): 1861-1869, 2017 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28733266
17.
T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.
Curr Opin Hematol;
22(6): 484-8, 2015 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26457961
18.
CD19 CAR-T therapy and sepsis: dancing with the devil.
Blood;
131(1): 7-8, 2018 01 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29301772
19.
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
Blood;
119(17): 3940-50, 2012 Apr 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22308288
20.
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
Clin Lymphoma Myeloma Leuk;
24(4): 240-253, 2024 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38195322